Fate Therapeutics
FATE
202 hedge funds and large institutions have $2.95B invested in Fate Therapeutics in 2020 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 73 increasing their positions, 50 reducing their positions, and 12 closing their positions.
383% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 12
75% more capital invested
Capital invested by funds: $1.68B → $2.95B (+$1.27B)
46% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 50
29% more funds holding
Funds holding: 156 → 202 (+46)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2.9% more ownership
Funds ownership: 99.57% → 102.47% (+2.9%)
7% less call options, than puts
Call options by funds: $7.17M | Put options by funds: $7.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
+$101M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$42.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$30.1M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$51.3M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$27.2M |
| 3 |
DM
Deerfield Management
New York
|
-$21M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$11.9M |
FATE Hedge Fund Activity: Q2 2020 in Review
202 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2020, worth a combined $2.95B — up 75% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new FATE positions and 12 closed out — a net gain of 46 holders — while 73 added to existing stakes and 50 trimmed.
The largest buyer was Johnson & Johnson Innovation - JJDC, opening a new position worth an estimated $101M. The largest seller was EcoR1 Capital, cutting an estimated $51.3M.
- 202 institutional investors held Fate Therapeutics (FATE) as of Q2 2020, up from 156 in Q1 2020.
- Funds reported $2.95B of Fate Therapeutics stock for Q2 2020, up 75% quarter-over-quarter.
- 58 funds opened new Fate Therapeutics positions in Q2 2020 and 12 closed out, a net change of +46 holders.
- The largest Fate Therapeutics buyer in Q2 2020 was Johnson & Johnson Innovation - JJDC, an estimated $101M added.
- The largest Fate Therapeutics seller in Q2 2020 was EcoR1 Capital, an estimated $51.3M sold.
Based on aggregated 13F filings for Q2 2020.